Gilead Sciences (NQ:GILD)

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill ↗

Today 13:28 EDT

Via Benzinga

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Today 10:00 EDT

Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗

June 29, 2026

Via Chartmill

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Today 10:00 EDT

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

3 Market-Beating Stocks with Solid Fundamentals

Today 0:31 EDT

Via StockStory

Topics Energy

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

July 20, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market...

Via Benzinga

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Topics ETFs

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Topics ETFs

Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. ↗

July 17, 2026

Via Investor's Business Daily

Topics Intellectual Property

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings ↗

July 16, 2026

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.

Via Benzinga

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗

July 14, 2026

RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Topics ETFs

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

July 13, 2026

Via StockStory

Topics Artificial Intelligence

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. ↗

July 12, 2026

Gilead's expansion beyond HIV therapies will surprise many investors.

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Topics Intellectual Property

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

You don't need to predict a recession to prepare your portfolio. These two stocks can help.

Topics ETFs

What's going on in today's session: S&P500 movers ↗

July 10, 2026

Via Chartmill

2 Recession-Resistant Dividend Stocks to Buy and Hold ↗

July 10, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Topics Economy

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

Topics ETFs

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗

July 08, 2026

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.

Topics ETFs

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

July 07, 2026

Via Chartmill

Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗

July 06, 2026

Via Benzinga

MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition

July 06, 2026

Via Investor Brand Network

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗

July 04, 2026

Compare fees, diversification, and risk between these two leading healthcare ETFs.

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

Topics ETFs

July 03, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market...

Via Benzinga

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗

July 02, 2026

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.

Topics ETFs

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗

June 25, 2026

Via Benzinga

This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗

June 25, 2026

It may not duplicate those impressive results, but it has all the tools it needs.

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Topics Artificial Intelligence ETFs Stocks

June 24, 2026